Recent Pfizer Press Releases

  • 1/14/19 8:00 am EST

    —FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial evaluating its efficacy, safety, andmore...
  • 1/3/19 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies.1,2 “We are proud to start this global pivotal Phase 2b/3 trial for PF-06651600 in patients withmore...
  • 12/31/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. To listen to themore...
  • 12/27/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, at the Goldman Sachs 11th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2019 at 10:15 a.m. Eastern Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. To listen to the webcast, visit our web site at www.pfizermore...
  • 12/20/18 4:30 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Phase 2b trial STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the company’s investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) is being discontinued due to futility. This decision is based on a recommendation from an independent Data Monitoring Committee (DMC), composed of external experts, after conducting a pre-more...
  • 12/20/18 9:00 am EST
    TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone. The preliminary safety analysis of the ARCHESmore...
  • 12/19/18 2:03 am EST

    Establishes a new focused global consumer healthcare business with the independence and sustainability to deliver significant value

    Equity split of 32% Pfizer and 68% GlaxoSmithKline

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global salesmore...
  • 12/18/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit ourmore...
  • 12/14/18 12:10 pm EST

    Board of Directors approves increase in quarterly cash dividend to $0.36 per share and authorizes new $10 billion share repurchase program

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfizer.more...
  • 12/14/18 10:29 am EST

    ZIRABEV (bevacizumab), a potential biosimilar to Avastin ®* (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab).1 ZIRABEV is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectablemore...